Executive summary: Japanese guidelines for adult asthma (JGL) 2021
-
- Niimi Akio
- Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences
-
- Fukunaga Koichi
- Pulmonary Division, Department of Medicine, Keio University School of Medicine
-
- Taniguchi Masami
- Center for Immunology and Allergology, Shonan Kamakura General Hospital
-
- Nakamura Yoichi
- Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital
-
- Tagaya Etsuko
- Department of Respiratory Medicine, Tokyo Women's Medical University
-
- Horiguchi Takahiko
- Department of Respiratory Medicine, Toyota Regional Medical Center
-
- Yokoyama Akihito
- Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University
-
- Yamaguchi Masao
- Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center
-
- Nagata Makoto
- Department of Respiratory Medicine, Saitama Medical University Allergy Center, Saitama Medical University Hospital, Saitama Medical University
抄録
<p>Asthma is characterized by chronic airway inflammation, variable airway narrowing, and sensory nerve irritation, which manifest as wheezing, dyspnea, chest tightness, and cough. Longstanding asthma may result in airway remodeling and become intractable. Despite the increased prevalence of asthma in adults, asthma-associated deaths have decreased in Japan (0.94 per 100,000 people in 2020). The goals of asthma treatment include the control of symptoms and reduction of future risks. A functional partnership between physicians and patients is indispensable for achieving these goals. Long-term management with medications and the elimination of triggers and risk factors are fundamental to asthma treatment. Asthma is managed via four steps of pharmacotherapy (“controllers”), ranging from mild to intensive treatments, depending on disease severity; each step involves daily administration of an inhaled corticosteroid, which varies from low to high dosage. Long-acting β2 agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonists are recommended as add-on drugs. Allergen immunotherapy is a new option that is employed as a controller treatment. Further, as of 2021, anti-IgE antibody, anti-IL-5 and anti-IL-5 receptor α-chain antibodies, and anti-IL-4 receptor α-chain antibodies are available for the treatment of severe asthma. Bronchial thermoplasty can be performed for asthma treatment, and its long-term efficacy has been reported. Algorithms for their usage have been revised. Comorbidities, such as allergic rhinitis, chronic rhinosinusitis, chronic obstructive pulmonary disease, and aspirin-exacerbated respiratory disease, should also be considered during the treatment of chronic asthma. Depending on the severity of episodes, inhaled short-acting β2 agonists, systemic corticosteroids, short-acting muscarinic antagonists, oxygen therapy, and other approaches are used as needed (“relievers”) during exacerbation.</p>
収録刊行物
-
- Allergology International
-
Allergology International 72 (2), 207-226, 2023
一般社団法人日本アレルギー学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390295812364560768
-
- ISSN
- 14401592
- 13238930
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
-
- 抄録ライセンスフラグ
- 使用不可